Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis.
Junji Akagi, Hideo Baba · Oncology reports · 2019
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 55 patients, univariate analysis showed that the ratio of the proportion of interme – diate PD-1+ CD8+ T cells following treatment with hydrogen gas to that prior to treatment (intermediate PD -1+ CD8 + T cell ratio) was significantly associated with shorter PFS (HR, 2.286; 95% CI, 1.284 -4.070; P=0.005) and OS (HR, 2.398; 95% CI, 1.384 -4.156; P=0.002) times. These findings add human evidence supporting molecular hydrogen's therapeutic potential for advanced colorectal cancer.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in 55 patients. Univariate analysis showed that the ratio of the proportion of interme – diate PD-1+ CD8+ T cells following treatment with hydrogen gas to that prior to treatment (intermediate PD -1+ CD8 + T cell ratio) was significantly associated with shorter PFS (HR, 2.286; 95% CI, 1.284 -4.070; P=0.005) and OS (HR, 2.398; 95% CI, 1.384 -4.156; P=0.002) times.
What the Researchers Studied
The researchers studied 55 patients. The study used a human clinical study.
What Effects Did Molecular Hydrogen Have?
The patients inhaled hydrogen gas for 3 h/day at their own homes and received chemotherapy at the Tamana Regional Health Medical Center (Tamana, Kumamoto, Japan). Univariate analysis showed that the ratio of the proportion of interme – diate PD-1+ CD8+ T cells following treatment with hydrogen gas to that prior to treatment (intermediate PD -1+ CD8 + T cell ratio) was significantly associated with shorter PFS (HR, 2.286; 95% CI, 1.284 -4.070; P=0.005) and OS (HR, 2.398; 95% CI, 1.384 -4.156; P=0.002) times. The authors concluded that the present results suggested that hydrogen gas reverses imbalances toward PD‑1+ CD8+ T cells to provide an improved prognosis. Accordingly, hydrogen is now believed to reduce oxidative stress and ischemia -reperfusion injury in the brain, spinal cord (10), myocardium (11), intestinal epithelium (12), retina, testes (13) and kidneys (14). Hydrogen has been used to treat various states associated with oxidative stress, including trauma (15), neurodegenerative disease (16), inflammatory disease (17), organ transplantation, metabolic syndrome (18), diabetes mellitus (19), sepsis (20), burns (21), adverse reac – tions to chemotherapy (22), radiation injury (23), hearing disorders and preeclampsia (24).
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for advanced colorectal cancer and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 55 patients. The reported sample size was 55. The study used a human clinical study. The hydrogen delivery method was inhaled hydrogen gas.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base. The original scholarly source is available at https://www.spandidos-publications.com/10.3892/or.2018.6841/download.